GEO DataSets

Analysis of ileum neuroendocrine tumor (NET) cell line CNDT2.5 treated with octreotide for up to 16 months. Somatostain analog octreotide is used to treat NET patients. Results provided insight into molecular basis of successful octreotide therapy or the development of drug resistance in NETs.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent, 5 cell line, 3 time sets

Platform:

GPL6244

Series:

GSE24358

8 Samples

Download data: CEL, CHP

(Submitter supplied) The management of neuroendocrine tumors (NETs) is very variable, depending on many specific aspects, such as the type of tumor, spread and patient general health. Several advances have been made with the newly developed somatostatin analogues to cure this type of malignancies. Somatostain analogues such as octreotide have been used in clinic to treat patients with neuroendocrine tumors (NETs). However, the molecular mechanism leading either to successful therapy or acquired resistance to the analogues is still to large extent unclear. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4330

Platform:

GPL6244

8 Samples

Download data: CEL, CHP

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens; Mus musculus

Type:

Expression profiling by array

Platforms:

GPL10558 GPL6885

87 Samples

Download data

(Submitter supplied) This study explores the hypothesis that stimulating the chemo-sensing olfactory receptor 51E1 (OR51E1) decreases SI-NET proliferation suggesting a mechanism that explains a difference in proliferative rate based on tumor location

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24676

2 Samples

Download data: XLSX